News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
PhD student Rose Foster wins ICR Science and Medical Imaging Competition
PhD student Rose Foster in the Prostate and Bladder Cancer Team in the Division of Radiotherapy and Imaging has won the ICR Science and Medical Imaging Competition 2022 for her image of a fluorescent image of bladder tumour tissue.
Scientists discover mechanism controlling spread of pancreatic cancer
Scientists have shown it is possible to reverse a key process that allows pancreatic cancer cells to grow and spread around the body.
Our research impact: PARP inhibitors
To mark our outstanding success in REF2021, Alison Halliday spoke to several of our researchers here at the ICR who were instrumental in the development of PARP inhibitors, a type of targeted drug that’s been approved for use in breast, ovarian and prostate cancer.
Drugs targeting cell recycling could be used to suffocate cancer cells
Pancreatic cancers recycle resources to fuel their survival and growth, opening up the possibility of new treatments aimed at stopping them from doing so, scientists report.
Study shows more women with invasive lobular breast cancer should qualify for tailored clinical trials
A new study led by scientists at The Institute of Cancer Research, London, has changed our understanding of invasive lobular breast cancer – and could increase the number of patients who access new treatments via lobular breast cancer specific clinical trials.
Spinal fluid analysis could speed up diagnosis of breast cancer spread
Analysing cancer DNA in spinal fluid could speed up and improve the diagnosis of breast cancer which has spread to the brain and spinal cord, according to a new pilot study.
ESMO Virtual Plenary 2022: Major trial shows targeted drug improves survival in early-stage breast cancer with inherited BRCA1 or BRCA2 mutation
The ICR strongly welcomes new findings that the targeted drug olaparib improves survival in women with high-risk, early-stage breast cancer who have inherited faults in their BRCA1 or BRCA2 genes.
ICR researchers named among world’s most influential scientists
Six researchers at the ICR and The Royal Marsden have been named in a list of the world's most influential by the by science analytics company Clarivate.
Liquid biopsies one step closer to entering the clinic to help guide breast cancer treatment
A simple blood test can identify specific genetic mutations in patients’ breast tumours to help guide their treatment and assess how likely patients are to relapse, a study shows.
ICR research showcased in world-first exhibition exploring cutting-edge cancer research
A new world-first exhibition by the Science Museum Group titled Cancer Revolution: Science, innovation and hope features a series of pioneering research projects being carried out at The Institute of Cancer Research, London.
Researchers find immune system link with rare ovarian cancer that could guide future treatment
Immune-related genes are associated with the development of the rare cancer ovarian clear cell carcinoma (OCCC), new research has found.
ASCO 2021: Trial shows benefits of targeted drug against early-stage breast cancer with inherited BRCA mutation
Women with high-risk, early-stage breast cancer who also have inherited faults in their BRCA1 or BRCA2 genes have shown a remarkable response to the targeted drug olaparib in a major clinical trial.
